Panmure Gordon analyst Dr Mike Mitchell spoke about Immupharma PLC this morning “This morning Immupharma has announced a detailed update on the progress of its phase III clinical trial of Lupuzor, progressing in conjunction with Simbec-Orion. The first sites in the US are expected to be fully initiated in late November/early December and will commence recruiting patients thereafter, with European sites expected to follow in January. We consider the progress provides evidence of momentum within the programme – completion expected by the end of 2017 – and look forward to further updates in due course.”

Learning About Lupus
May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system